Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

School-Based Program Helps Prevent Dating Violence Among Teens, Especially Boys
A school-based program that integrates information about healthy relationships into the existing ninth-grade curriculum appears to reduce adolescent dating violence and increase condom use two and a half years later, according to a report in the August issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. The effects of the low-cost intervention appear stronger in boys.
generic viagra online
Physicians Offer Practical Tips On Preventing Strokes And Their Lasting Effects
It takes less than a minute for a stroke to change a person"s life forever, but taking the time to make a few simple lifestyle adjustments and finding out how to recognize an attack when it happens can save thousands of lives.
News of the day
Findings In Epilepsy Gene In Animals May Guide Treatment Directions For Infants
Researchers studying a difficult-to-treat form of childhood epilepsy called infantile spasms have developed a line of mice that experiences seizures with features closely resembling those occurring in patients with infantile seizures. These genetically engineered mice provide a new opportunity for scientists to test treatments that may benefit children.
Cardiovascular

Experimental MS Drug Withdrawn From Trial

An experimental treatment for multiple sclerosis (MS) has been withdrawn from clinical trials after it failed to delay progression of the condition in a late-stage trial. Dirucotide, manufactured by Eli Lilly and Co and BioMS Medical Corp, had earlier failed to meet a main goal in a mid-stage study, which tested whether the drug prevented symptoms returning among patients with relapsing remitting MS. The drugmakers, which have been collaborating since late 2008 on dirucotide, said the latest negative results were seen in a study of the drug that involved 612 patients with secondary progressive (MS). Patients in the study were divided into groups that received either dirucotide or a placebo intravenously every six months for two years. In addition to failing its primary goal of delaying the time it took for the condition to worsen in patients, the drug also failed a number of secondary goals. "We are obviously disappointed by this result and will be working closely with our clinical team to evaluate these data," BioMS Medical Chief Executive Kevin Giese said in a statement. Multiple Sclerosis Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009